|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Disease impact on the quality of life of children with inflammatory bowel disease显示文摘AIM To assess the impact of disease characteristics on the quality of life (QOL) in children with inflammatory bowel diseases(IBD).METHODS This was a cross-sectional study conducted at the First Department of Pediatrics of the University of Athens at the 'Aghia Sophia' Children's Hospital. Children diagnosed with Crohn's disease (CD) or ulcerative colitis (UC), who were followed as outpatients or during a hospitalization, participated, after informed consent was obtained from their legal representative. QOL was assessed by the IMPACT-III questionnaire. Demographic data and disease characteristics were also collected. Statistical analyses included parametric(Student's t-test and Pearson's r) and non-parametric(Mann-Whitney test, Fisher's test and Spearman's rho) procedures.RESULTS Ninety-nine patients (UC: 37, 73.0% females, CD: 62, 51.6% females), aged 12.8±2.6 years were included.Overall, as well as, sub-domain scores did not differ between UC and CD(overall score: 73.9±13.3 vs 77.5±11.2, respectively, P=0.16). In the entire sample, total score was related to physician's global assessment(PGA, patients classified as 'mild/moderate' active disease had, on average, 14.8±2.7 points lower total scores compared to those 'in remission', P<0.001) and age at IMPACT completion (Pearson's r=0.29, P=0.05). Disease activity assessed by the indices Pediatric Ulcerative Colitis activity index, Pediatric Crohn's disease activity index or PGA was significantly associated with all subdomains scores. Presence of extraintestinal manifestations had a negative impact on emotional and social functioning domains.CONCLUSION Disease activity is the main correlate of QOL in children with IBD, underlining the importance of achieving and sustaining clinical | Giorgos Chouliaras Daphne Margoni Konstantina Dimakou Smaragdi Fessatou Ioanna Panayiotou Eleftheria Roma-Giannikou | 2017 | World Journal of Gastroenterology2017，23，6： | 4 |
| 2 | Hepatitis C in hemodialysis patients显示文摘Despite reduction of hepatitis C prevalence after recognition of the virus and testing of blood products, hemodialysis(HD) patients still comprise a high risk group. The natural history of hepatitis C virus(HCV) infection in dialysis is not fully understood while the clinical outcome differs from that of the general population. HD patients show a milder liver disease with lower aminotransferase and viral levels depicted bymilder histological features on liver biopsy. Furthermore, the 'silent' clinical course is consistent with a slower disease progression and a lower frequency of cirrhosis and hepatocellular carcinoma. Potential explanations for the 'beneficial' impact of uremia and hemodialysis on chronic HCV infection are impaired immunosurveillance leading to a less aggressive host response to the virus and intradialytic release of 'hepatoprotective' cytokines such as interferon(IFN)-α and hepatocyte growth factor. However, chronic hepatitis C is associated with a higher liver disease related cardiovascular and allcause mortality of HD patients. Therapy is indicated in selected patients groups including younger patients with low comorbidity burden and especially renal transplant candidates, preferably after performance of a liver biopsy. According to current recommendations, choice of treatment is IFN or pegylated interferon with a reported sustained viral response at 30%-40% and a withdrawal rate ranging from 17% to 30%. New data regarding combination therapy with low doses of ribavirin which provide higher standard variable rates and good safety results, offer another therapeutic option. The new protease inhibitors may be the future for HCV infected HD patients, though data are still lacking. | Smaragdi Marinaki John N Boletis Stratigoula Sakellariou Ioanna K Delladetsima | 2015 | World Journal of Hepatology2015，7，3： | 2 |
| 3 | Excellent long term patient and renal allograft survival after ABO-incompatible kidney transplantation:Experience of one center显示文摘AIM: To investigate the long-term results of ABOincompatible(ABOi) kidney transplantation in a single center in Greece.METHODS: Thirty consecutive ABOi kidney transplantations were performed from June 2005 to December 2013. All patients received rituximab one month prior to transplantation. Immunoadsorption therapy was performed for the removal of anti-A/B Ig G antibodies until the titer was ≤ 1:16. Additional apheresis sessions were performed post-operatively. Intravenous immunoglobulin and oral immunosuppression consisting of tacrolimus(TAC) in combination with either everolimus or mycophenolate acid was administered. We compared the long term results of our ABOi group to those of a matched group of 30 ABO compatible(ABOc) living kidney recipients with similar baseline characteristics. The ABOc recipients received an immunosuppressive regimen consisting of TAC and mycophenolate acid. All patients in both groups received induction therapy with Basiliximab or Daclizumab, whereas corticosteroids were instituted on the day of surgery. During the followup period, indication biopsies were performed and interpreted by an experienced nephropathologist. The parameters we analyzed included the following: Donor/recipient age, gender, blood type, human leukocyte antigen mismatches, panel reactive antibodies, primary cause of renal failure, mean time on dialysis, immunosuppressive regimen, patient survival, graft outcome, incidence of rejections, surgical and infectious complications.RESULTS: The mean follow-up period was 6 years(range 1 to 9 years). A mean of 5.0 ± 3.0(range 0-14) pre-transplant immunoadsorptions were required in order to reach the target titer. Patient survival in ABOi group in comparison to ABOc group at 1, 3, 5 and 8 years did not differ significantly(100% vs 100%, 96% vs 100%, 92% vs 100% and 92% vs 100%, P = ns). Additionally, graft survival was similar in the two groups at the same time points(100% vs 100%, 96% vs 96%, 92% vs 96% and 81% vs 92%, P = ns). The mean serum creatinine and the estimated glomerular filtration rate by the modification of diet in renal disease formula at 1, 3, 5 and 8 years did not differ significantly between ABOi and ABOc group. None of the patients in the ABOi group developed acute or chronic antibodymediated rejection evidenced by histological signs. Four patients(13.3%) in the ABOi group and 3(10%) in the ABOc group experienced acute cellular rejection, which was treated successfully in all cases. Bacterial and viral infections were also similar between the two groups.CONCLUSION: ABOi kidney transplantation is a safe and effective alternative that enables kidney transplantation in countries with unacceptably long deceaseddonor waiting lists. | Christina Melexopoulou Smaragdi Marinaki George Liapis Chrysanthi Skalioti Maria Gavalaki George Zavos John N Boletis | 2015 | World Journal of Transplantation2015，5，4： | 2 |
| 4 | Blind separation of convolved mixtures in the frequency domain 显示文摘 | Seki K Narusawa M Smaragdis P | 1998 | Neurocomputing1998，22，14： | 1 |
| 5 | Antioxidant and lipoxygenase inhibitory activities of pumpkin seed extracts显示文摘 | Marianna N. Xanthopoulou Tzortzis Nomikos Elizabeth Fragopoulou Smaragdi Antonopoulou | 2009 | Food Research International2009，，5： | 1 |
| 6 | Convolutive speech bases and their ap- plication to supervised speech separation显示文摘 | Smaragdis P | 2007 | IEEE Trans on Audio Speech and Language Processing2007，15，1： | 1 |
| 7 | Convolution speech bases and their application to supervised speech separation 显示文摘 | SMARAGDIS P | 2007 | IEEE Transactions on Audio Speech and Language Processing2007，15，1： | 1 |
| 8 | Blind separation of convolved mixtures in the frequency domain 显示文摘 | Smaragdis P | 1998 | Neurocomputing1998，22，13： | 1 |
| 9 | The markov selection model for concurrent speech recognition 显示文摘 | Paris Smaragdis Bhiksha Raj | 2011 | Neuro computing2011，79，7： | 1 |
| 10 | Supervised and unsuper- vised speech enhancement using nonnegative matrix factorization 显示文摘 | MOHAMMADIHA N SMARAGDIS P | 2013 | IEEE Transactions on Audio Speech and Language Process- ing2013，20，1： | 1 |
| 11 | A flow-maximizing adaptive local ramp metering strategy显示文摘 | Smaragdis E Papageorgiou M Kosmatopoulos E | 2004 | Transportation Research Part B2004，38，： | 1 |
| 12 | Convolutive speech bases and their application to supervised speech separation 显示文摘 | P Smaragdis | 2007 | IEEE Trans on Audio Speech and Language Processing2007，15，1： | 1 |
| 13 | Blind separation of convolved mixtures in the frequency domain显示文摘 | SMARAGDIS P | 1998 | Neurocomputing1998，22，13： | 1 |
| 14 | Blind separation of convolved mixtures in the frequency domain显示文摘 | Smaragdis P | 1998 | Neurocomputing1998，22，： | 1 |
| 15 | The Markov selection model for concurrent speech recognition 显示文摘 | SMARAGDIS P RAJ B | 2012 | Neurocomputing2012，80，： | 1 |
| 16 | Blind Separation of Convolved Mixtures in the Frequency Domain显示文摘 | Smaragdis P | 1998 | Neurocomput1998，22，： | 1 |
| 17 | Sparse overcomplete latent variable decomposition of counts data显示文摘 | Shashanka M Raj B Smaragdis P | | 0，，01： | 1 |
| 18 | A flow-maximizing adaptive local ramp metering strategy 显示文摘 | Smaragdis E Papageorgiou M Kosmatopoulos E | 2004 | Transportation Research Part B2004，38，3： | 1 |
| 19 | A flow-maximizing adaptive local ramp metering str7ategy显示文摘 | Smaragdis E Papageorgiou M Kosmatopoulos E | 2004 | Transportation Research Part B2004，38，： | 1 |
| 20 | Blind separation of convolved mixtures in the frequency domain 显示文摘 | Smaragdis P | 1998 | Neurocomputing1998，22，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员